Inventor
HENRYK T. DUDEK
Inventor
US
Overview
Patents· 20 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes15%
C12YEnzymes15%
C07HSugars3%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
12,534,730Compositions and methods for inhibiting GYS2 expression202612,435,336Compositions and methods for inhibiting LPA expression202512,252,691Compositions and methods for inhibiting LPA expression202512,084,662Compositions and methods for modulating PNPLA3 expression202411,912,996Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202411,873,493Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA202411,851,658Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202311,773,390Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA202311,697,812Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA202311,667,918Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA202311,661,604Methods and compositions for inhibiting expression of LDHA202311,572,562Compositions and methods for inhibiting GYS2 expression202311,566,248PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions202311,459,566Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202211,408,002Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202211,359,203Therapeutic inhibition of lactate dehydrogenase and agents therefor202211,312,960Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202211,312,961Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA202211,286,488Methods and compositions for inhibiting expression of LDHA202211,208,658Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2025Patents assigned to DICERNA PHARMACEUTICALS INC (19)· patent assignee history
2021–2026Based in US· patent location history
2026Patents assigned to NOVO NORDISK AS (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| DICERNA PHARMACEUTICALS INC | 19 | 2021–2025 |
| NOVO NORDISK AS | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 20 | 2021–2026 |